Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 7Gynecologic 6Gastrointestinal 6Other hematologic neoplasm 5Lymphoid 5Thoracic 3Myeloid 3NET 2Genitourinary 2Endocrine 2Classical hematology 2CNS 2Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
3-aminopyridine-2-carboxaldehyde thiosemicarbazone × Genitourinary × Clear all
NCT00075660 2023-08-04

3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma

Canadian Cancer Trials Group

Phase 2 Completed
19 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00054015 2013-11-06

3-AP in Treating Patients With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡